Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19
The Pharma Data
MARCH 25, 2022
There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, 7,8) This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.(7).
52 
Let's personalize your content